Omnicell (OMCL) valuation check as new Titan XT automation platform targets healthcare growth

Simply Wall St.02:17

Omnicell (OMCL) just rolled out Titan XT, a new enterprise level automated dispensing system built on its OmniSphere cloud platform, and the launch is already reshaping how investors think about the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593245430?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2025-12-23 02:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593245430","market":"sg","top_or_hot":-1,"title":"Omnicell (OMCL) valuation check as new Titan XT automation platform targets healthcare growth","media":"Simply Wall St.","content":"<div>\n<p>Omnicell (OMCL) just rolled out Titan XT, a new enterprise level automated dispensing system built on its OmniSphere cloud platform, and the launch is already reshaping how investors think about the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-valuation-check-as-new-titan-xt-automation-pla\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omnicell (OMCL) valuation check as new Titan XT automation platform targets healthcare growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmnicell (OMCL) valuation check as new Titan XT automation platform targets healthcare growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 02:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-valuation-check-as-new-titan-xt-automation-pla><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Omnicell (OMCL) just rolled out Titan XT, a new enterprise level automated dispensing system built on its OmniSphere cloud platform, and the launch is already reshaping how investors think about the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-valuation-check-as-new-titan-xt-automation-pla\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-valuation-check-as-new-titan-xt-automation-pla","article_id":"2593245430","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-valuation-check-as-new-titan-xt-automation-pla","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593245430","pubTimestamp":1766427476,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Omnicell (OMCL) just rolled out Titan XT, a new enterprise level automated dispensing system built on its OmniSphere cloud platform, and the launch is already reshaping how investors think about the stock.\nSee our latest analysis for Omnicell.\nThe launch of Titan XT coincides with Omnicell’s 30 day share price return of 30.11 percent and 90 day share price return of 51.10 percent, which signal rapidly building momentum. However, the 5 year total shareholder return of negative 60.02 percent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell","XT":"iShares Exponential Technologies ETF","BK4082":"医疗保健设备","BK4167":"医疗保健技术","TWI":"泰坦国际","BK4152":"农用农业机械"},"translate_title":"Omnicell(OMCL)估值检查，新的Titan XT自动化平台瞄准医疗保健增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWI":1.5,"XT":1.5,"OMCL":1.5},"content_text":"Omnicell (OMCL) just rolled out Titan XT, a new enterprise level automated dispensing system built on its OmniSphere cloud platform, and the launch is already reshaping how investors think about the stock. See our latest analysis for Omnicell. The launch of Titan XT coincides with Omnicell’s 30 day share price return of 30.11 percent and 90 day share price return of 51.10 percent, which signal rapidly building momentum. However, the 5 year total shareholder return of negative 60.02 percent indicates that long term holders are still waiting for a full turnaround. If this kind of healthcare automation story has your attention, it could be worth scanning other promising healthcare stocks that might be flying under your radar. With shares rebounding but still well below five year highs and trading only modestly under analyst targets, the key question now is whether Omnicell remains undervalued or if the market is already pricing in Titan powered growth. Most Popular Narrative: 9% Undervalued With Omnicell last closing at 46.84 dollars against a narrative fair value of 51.50 dollars, expectations are quietly running ahead of the current quote.  The continued rollout and adoption of the cloud native OmniSphere platform across Omnicell's customer base will simplify enterprise wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher margin, recurring SaaS based revenues, supporting improved revenue predictability and net margins.  Read the complete narrative. Want to see what kind of revenue runway and margin shift are baked into that optimism? The real surprise is how rich the future earnings multiple needs to be to keep this story intact. Curious which assumptions have to hold for that to work? Result: Fair Value of $51.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, tariff driven cost pressure and slower than expected SaaS mix shift could quickly undermine the optimism embedded in Titan powered earnings assumptions. Find out about the key risks to this Omnicell narrative. Another View: Multiples Flash a Caution Sign While narrative fair value suggests modest upside, the current price implies a 105.5x earnings multiple. This is far richer than both the US Medical Equipment industry at 29.7x and peers at 23.3x, and well above a 34.9x fair ratio. Could sentiment be running ahead of fundamentals again? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:OMCL PE Ratio as at Dec 2025 Build Your Own Omnicell Narrative If you see the story differently or want to dig into the numbers yourself, you can build a custom view in just minutes: Do it your way. A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Omnicell. Looking for your next smart move? Before markets shift again, secure your edge by running fresh ideas through the Simply Wall Street Screener and lining up your next high conviction opportunities.  Capture potential mispricings by running these 900 undervalued stocks based on cash flows and line up candidates where expectations still lag the underlying cash flows. Ride structural growth trends by targeting these 24 AI penny stocks positioned at the heart of machine learning and automation demand. Strengthen long term income potential by focusing on these 12 dividend stocks with yields > 3% that combine resilient cash generation with ongoing shareholder payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593245430","isCrawlerRequest":true}